Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110915 | 0.93 | ADORA2A (0.42) | ADORA2AADORA3HRH4HRH3 | |
| SCHEMBL4121487 | 0.93 | ADORA2A (0.42) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL4122816 | 0.93 | ADORA2A (0.46) | ADORA2AADORA3SYKHRH4HRH3 | |
| SCHEMBL241435 | 0.93 | ADORA2A (0.47) | ADORA2AADORA3 | |
| SCHEMBL4122715 | 0.92 | ADORA2A (0.44) | ADORA2AADORA3 | |
| SCHEMBL4129318 | 0.91 | ADORA2A (0.45) | ADORA2AADORA3 | |
| SCHEMBL1402054 | 0.88 | ADORA2A (0.42) | ADORA2AADORA3HRH4HRH3 | |
| SCHEMBL1402087 | 0.88 | ADORA2A (0.43) | ADORA2AADORA3HRH4HRH3 | |
| SCHEMBL2091170 | 0.87 | ADORA2A (0.36) | ADORA2AADORA3HRH4HRH3 | |
| SCHEMBL1402084 | 0.87 | ADORA2A (0.36) | ADORA2AADORA3HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099214-A1 | Organic Compounds | CYP3A43, OXER1, OPRM1 | ADORA2A 2082/4885ADORA3 554/4885SYK 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.